Drug repurposing to fight colistin and carbapenem-resistant bacteria
Open accessAbstract
The emergence of new resistance mechanisms, the failure of classical antibiotics in clinic, the decrease in the development of antibiotics in the industry are all challenges that lead us to consider new strategies for the treatment of infectious diseases. Indeed, in recent years controversy has intensified over strains resistant to carbapenem and/or colistin. Various therapeutic solutions are used to overcome administration of last line antibiotics. In this context, drug repurposing, which consists of using a non-antibiotic compound to treat multi-drug resistant bacteria (MDR), is encouraged. In this review, we first report what may have led to drug repurposing. Main definitions, advantages and drawbacks are summarized. Three major methods are described: phenotypic, computational and serendipity. In a second time we will focus on the current knowledge in drug repurposing for carbapenem and colistin-resistant bacteria with different studies describing repurposed compounds tested on Gram-negative bacteria. Furthermore, we show that drug combination therapies can increase successful by drug repurposing strategy. In conclusion, we discuss the pharmaceutical industries that have little interest in reprofiling drugs due to lack of profits. We also consider what a clinician might think of the indications of these uncommon biologists to treat MDR bacterial infections and avoid therapeutic impasses.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Synergistic combinations could reduce antibiotic concentrations, reducing toxic side effects and preventing resistance.
“This is a positive outcome, as these synergistic combinations could reduce the antibiotic concentrations used to treat an infection, in parallel reducing the toxic side effects and preventing the development of resistance [31].”
From Antimicrobial Properties of Antidepressants and Antipsychotics—Possibilities and Implications (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237 · see citing works
Antibiotic resistance: a rundown of a global crisis
Aslam, B., Wang, W., Arshad, M. I., Khurshid, M., Muzammil, S., Rasool, M. H., Nisar, M. A., Alvi, R. F., Aslam, M. A., Qamar, M. U., et al. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s173867 · Cited by 2,581 · see citing works
The global threat of antimicrobial resistance: science for intervention.
Roca, I., Akova, M., Baquero, F., Carlet, J., Cavaleri, M., Coenen, S., Cohen, J., Findlay, D., Gyssens, I., Heure, O. E., et al. (2015) · New Microbes and New Infections · doi:10.1016/j.nmni.2015.02.007 · Cited by 1,106 · see citing works
Self-citationTrends in antimicrobial drug development: Implications for the future
Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/420937 · Cited by 867 · see citing works
Kadri, S. S., Adjemian, J., Lai, Y. L., Spaulding, A. B., Ricotta, E., Prevots, D. R., Palmore, T. N., Rhee, C., Klompas, M., Dekker, J. P., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy378 · Cited by 617 · see citing works
Colistin: an update on the antibiotic of the 21st century
Biswas, S., Brunel, J. M., Dubus, J. ‐., Reynaud‐Gaubert, M., & Rolain, J. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.78 · Cited by 580 · see citing works
Self-citationDrug combination therapy increases successful drug repositioning
Sun, W., Sanderson, P. E. J., & Zheng, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.05.015 · Cited by 438 · see citing works
Stokes, J. M., MacNair, C. R., Ilyas, B., French, S., Côté, J., Bouwman, C., Farha, M. A., Sieron, A. O., Whitfield, C., Coombes, B. K., et al. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.28 · Cited by 335 · see citing works
In silico methods for drug repurposing and pharmacology
Hodos, R. A., Kidd, B. A., Shameer, K., Readhead, B., & Dudley, J. T. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1337 · Cited by 333 · see citing works
Goss, C., Kaneko, Y., Khuu, L., Anderson, G., Ravishankar, S., Aitken, M., Lechtzin, N., Zhou, G.-L., Czyż, D. M., McLean, K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7520 · Cited by 330 · see citing works
Sleire, L., Førde, H. E., Netland, I. A., Leiss, L., Skeie, B. S., & Enger, P. Ø. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.013 · Cited by 329 · see citing works
Drug repositioning and repurposing: terminology and definitions in literature
Langedijk, J., Mantel-Teeuwisse, A. K., Slijkerman, D. S., & Schutjens, M.-H. D. B. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.001 · Cited by 327 · see citing works
History of Antibiotics Research
Mohr, K. I. (2016) · Current topics in microbiology and immunology · doi:10.1007/82_2016_499 · Cited by 296 · see citing works
Olaitan, A. O., Diene, S. M., Kempf, M., Berrazeg, M., Bakour, S., Gupta, S. K., Thongmalayvong, B., Akkhavong, K., Somphavong, S., Paboriboune, P., et al. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.07.020 · Cited by 292 · see citing works
Self-citationA new strategy to fight antimicrobial resistance: the revival of old antibiotics
Cassir, N., Rolain, J., & Brouqui, P. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00551 · Cited by 280 · see citing works
Self-citationAntimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach
Bassetti, M., Poulakou, G., Ruppé, É., Bouza, E., van Hal, S. J., & Brink, A. J. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4878-x · Cited by 278 · see citing works
Antibiotics: from prehistory to the present day
Gould, K. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv484 · Cited by 272 · see citing works
Drug Repurposing for Viral Infectious Diseases: How Far Are We?
Mercorelli, B., Palù, G., & Loregian, A. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2018.04.004 · Cited by 264 · see citing works
Food and human gut as reservoirs of transferable antibiotic resistance encoding genes
Rolain, J. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00173 · Cited by 258 · see citing works
Self-citationDrug repurposing screens and synergistic drug‐combinations for infectious diseases
Zheng, W., Sun, W., & Simeonov, A. M. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13895 · Cited by 248 · see citing works
Antibiotics in late clinical development
FERNANDES, P. B., & Martens, E. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.09.025 · Cited by 247 · see citing works
Monaco, M., Giani, T., Raffone, M., Arena, F., García-Fernández, A., Pollini, S., collective Network EuSCAPE-Italy, Grundmann, H., Pantosti, A., & Rossolini, G. M. (2014) · Eurosurveillance · doi:10.2807/1560-7917.es2014.19.42.20939 · Cited by 224 · see citing works
Drug Repurposing for the Treatment of Bacterial and Fungal Infections
Miró-Canturri, A., Ayerbe-Algaba, R., & Smani, Y. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00041 · Cited by 210 · see citing works
Where are all the new antibiotics? The new antibiotic paradox
Conly, J. M., & Johnston, B. (2005) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2005/892058 · Cited by 187 · see citing works
Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U)
Elwell, L. P., Ferone, R., Freeman, G. A., Fyfe, J. A., Hill, J. A., Ray, P. H., Richards, C. A., Singer, S. C., Knick, V. B., & Rideout, J. L. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.2.274 · Cited by 161 · see citing works
Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections
Rangel-Vega, A., Bernstein, L., Mandujano-Tinoco, E., García-Contreras, S. J., & García-Contreras, R. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00282 · Cited by 158 · see citing works
Antimicrobial Activity of Gallium Compounds on ESKAPE Pathogens
Hijazi, S., Visaggio, D., Pirolo, M., Frangipani, E., Bernstein, L., & Visca, P. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00316 · Cited by 144 · see citing works
Trends in antimicrobial drug development: Implications for the future
Sergio Mella, M. (2005) · Revista chilena de infectología · doi:10.4067/s0716-10182005000200011 · Cited by 143 · see citing works
D’Angelo, F., Baldelli, V., Halliday, N., Pantalone, P., Polticelli, F., Fiscarelli, E. V., Williams, P. M., Visca, P., Leoni, L., & Rampioni, G. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01296-18 · Cited by 116 · see citing works
Synergistic combinations of polymyxins
Lenhard, J. R., Nation, R. L., & Tsuji, B. T. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.09.014 · Cited by 108 · see citing works
Seukep, A. J., Sandjo, L. P., Ngadjui, B. T., & Kuete, V. (2016) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1173-2 · Cited by 102 · see citing works
Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections.
Soo, V. W. C., Kwan, B. W., Quezada, H., Castillo-Juárez, I., Pérez-Eretza, B., García-Contreras, S. J., Martínez-Vázquez, M., Wood, T., & García-Contreras, R. (2017) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160930131737 · Cited by 100 · see citing works
Davido, B., Batista, R., Michelon, H., et al. (2017) · Journal of Hospital Infection · doi:10.1016/j.jhin.2017.02.001 · Cited by 95 · see citing works
Drug repurposing: a better approach for infectious disease drug discovery?
Law, G. L., Tisoncik-Go, J., Korth, M. J., & Katze, M. G. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.08.004 · Cited by 90 · see citing works
Torres, N. S., Abercrombie, J. J., Srinivasan, A., Lopez-Ribot, J. L., Ramasubramanian, A. K., & Leung, K. P. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00377-16 · Cited by 86 · see citing works
Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer's Disease
Kim, T. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0325-7 · Cited by 82 · see citing works
Sun, W., Weingarten, R. A., Xu, M., Southall, N. T., Dai, S., Shinn, P., Sanderson, P. E. J., Williamson, P. R., Frank, K. M., & Zheng, W. (2016) · Emerging Microbes & Infections · doi:10.1038/emi.2016.123 · Cited by 82 · see citing works
Schneider‐Futschik, E. K., Reyes‐Ortega, F., Velkov, T., & Li, J. (2017) · Essays in Biochemistry · doi:10.1042/ebc20160058 · Cited by 76 · see citing works
Ayerbe-Algaba, R., Gil-Marqués, M. L., Me, J.-M., Sánchez-Encinales, V., Parra-Millán, R., Pachón-Ibáñez, M. E., Pachón, J., & Smani, Y. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00348 · Cited by 76 · see citing works
Carlson-Banning, K. M., Chou, A., Liu, Z., Hamill, R. J., Song, Y., & Zechiedrich, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069646 · Cited by 73 · see citing works
CRISPR/Cas9-The ultimate weapon to battle infectious diseases?
Doerflinger, M., Forsyth, W. O., Ebert, G., Pellegrini, M., & Herold, M. J. (2016) · Cellular Microbiology · doi:10.1111/cmi.12693 · Cited by 72 · see citing works
Wang, Y.-M., Kong, L., Liu, J., & Ma, H. (2018) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-018-0303-7 · Cited by 66 · see citing works
Zenati, K., Touati, A., Bakour, S., Sahli, F., & Rolain, J. (2015) · Journal of Hospital Infection · doi:10.1016/j.jhin.2015.09.020 · Cited by 62 · see citing works
Self-citationHussein, M. H., Schneider‐Futschik, E. K., Elliott, A. G., et al. (2016) · Microbial Drug Resistance · doi:10.1089/mdr.2016.0196 · Cited by 59 · see citing works
Pterostilbene, a Potential MCR-1 Inhibitor That Enhances the Efficacy of Polymyxin B
Zhou, Y., Liu, S., Wang, T., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02146-17 · Cited by 59 · see citing works
Doléans-Jordheim, A., Bergeron, E., Bereyziat, F., et al. (2011) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-011-1220-3 · Cited by 53 · see citing works
Otto, R. G., van Gorp, E., Kloezen, W., et al. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.09.003 · Cited by 53 · see citing works
Hu, Y., Liu, Y., & Coates, A. R. M. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01630-18 · Cited by 53 · see citing works
Hashemi, M., Rovig, J., Weber, S., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00292-17 · Cited by 52 · see citing works
Cannatelli, A., Principato, S., Colavecchio, O. L., Pallecchi, L., & Rossolini, G. M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01808 · Cited by 51 · see citing works
Cheng, Y., Sun, W., Xu, M., Shen, M., Khraiwesh, M. H., Sciotti, R. J., & Zheng, W. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00438 · Cited by 47 · see citing works
Bachiri, T., Bakour, S., Lalaoui, R., et al. (2017) · Microbial Drug Resistance · doi:10.1089/mdr.2016.0323 · Cited by 46 · see citing works
The Future of Drug Repositioning
Doan, T. L., Pollastri, M. P., Walters, M. A., & Georg, G. I. (2011) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-386009-5.00004-7 · Cited by 45 · see citing works
Ng, S. M. S., Sioson, J. S. P., Yap, J. M., Ng, F. M., Ching, H. S. V., Teo, J. W. P., Jureen, R., Hill, J., & Chia, C. S. B. (2017) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-017-3114-5 · Cited by 44 · see citing works
Tran, T. B., Wang, J., Doi, Y., Velkov, T., Bergen, P. J., & Li, J. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00721 · Cited by 44 · see citing works
Rolain, J., & Baquero, F. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.03.026 · Cited by 43 · see citing works
Self-citationA Novel Alkaliphilic Streptomyces Inhibits ESKAPE Pathogens
Terra, L., Dyson, P. J., Hitchings, M. D., Thomas, L., Abdelhameed, A., Banat, I. M., Gazze, S. A., Vujaklija, D., Facey, P. D., Francis, L. W., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02458 · Cited by 42 · see citing works
Drug repurposing may generate novel approaches to treating depression
Ebada, M. E. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12815 · Cited by 33 · see citing works
Control of Multidrug-Resistant Gene Flow in the Environment Through Bacteriophage Intervention
Parmar, K. M., Hathi, Z. J., & Dafale, N. A. (2016) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-016-2265-7 · Cited by 31 · see citing works
Cebrero-Cangueiro, T., Álvarez‐Marín, R., Labrador-Herrera, G., Smani, Y., Cordero, E., Pachón, J., & Pachón-Ibáñez, M. E. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00363 · Cited by 31 · see citing works
Diene, S. M., & Rolain, J. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.13.1 · Cited by 30 · see citing works
Self-citationScaffold Repurposing of Old Drugs Towards New Cancer Drug Discovery
Chen, H., Wu, J., Gao, Y., Chen, H., & Zhou, J. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160216155556 · Cited by 29 · see citing works
Zidovudine: A salvage therapy for mcr-1 plasmid-mediated colistin-resistant bacterial infections?
Peyclit, L., Baron, S. A., Yousfi, H., et al. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.03.012 · Cited by 28 · see citing works
Self-citationLoose, M., Naber, K. G., Hu, Y., et al. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.08.010 · Cited by 27 · see citing works
Okdah, L., Page, S. L., Olaitan, A. O., et al. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.01.027 · Cited by 22 · see citing works
Tafoukt, R., Leangapichart, T., Hadjadj, L., et al. (2017) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2017.11.008 · Cited by 20 · see citing works
Zidovudine-resistance in Saimonella typhimurium and Escherichia coli
Lewin, C. S., ALLEN, R., & Amyes, S. G. B. (1990) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/25.4.706 · Cited by 19 · see citing works
Antibacterial activity of fluoroquinolones in combination with zidovudine
Lewin, C. S., ALLEN, R. A., & Amyes, S. G. B. (1990) · Journal of Medical Microbiology · doi:10.1099/00222615-33-2-127 · Cited by 19 · see citing works
Yang, Y., & Chua, K. L. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.05.011 · Cited by 18 · see citing works
Martínez-Torró, C., Torres-Puig, S., Monge, M., Sánchez-Alba, L., González-Martín, M., Marcos-Silva, M., Perálvarez‐Marín, A., Canals, F., Querol, E., Piñol, J., et al. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1700762 · Cited by 11 · see citing works
Mascellino, M. T., Iona, E., Iegri, F., et al. (1993) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.1993.tb00377.x · Cited by 10 · see citing works
Sun, J., Yang, J., Chi, J., Ding, X., & Lv, N. (2018) · Human Genomics · doi:10.1186/s40246-018-0184-0 · Cited by 8 · see citing works
[Treatment for diabetes with sulfamide hypoglycemic agents].
Deuil, R. (1956) · PubMed · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Antimicrobial Properties of Antidepressants and Antipsychotics—Possibilities and Implications
Caldara, M., & Marmiroli, N. (2021) · Pharmaceuticals · doi:10.3390/ph14090915 · Cited by 54 · see citing works
- Authors
- Peyclit, L., Baron, S. A., & Rolain, J.-M.
- Affiliations
- Aix-Marseille Université (FR)
- Corresponding author
- Rolain, Jean-Marc
- Venue
- Frontiers in Cellular and Infection Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2019-06-11
- Volume
- 9
- Pages
- 193-193
- ISSN
- 2235-2988 (ISSN-L)
- PMC
- PMC6579884
- OpenAlex
- W2950560626
- Cited by
- 91
- References
- 73
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 13 · 2023: 13 · 2022: 16 · 2021: 20 · 2020: 11 · 2019: 2 · 2017: 1
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Cellular and Infection Microbiology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Agence Nationale de la Recherche (Méditerranée Infection 10-IAHU-03)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Antibiotic Resistance in Bacteria
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Antibiotic Use and Resistance
- Physical Sciences › Chemistry › Organic Chemistry › Antimicrobial agents and applications
- Keywords
- drug repurposing, colistin resistance, carbapenem resistance, multidrug-resistant bacteria, Gram-negative bacteria, phenotypic screening, computational drug repurposing, serendipitous drug discovery, drug combination therapy, last-resort antibiotics, pharmaceutical industry incentives
- MeSH terms
- Anti-Bacterial Agents, Colistin, Drug Combinations, Gram-Negative Bacteria, Humans, Carbapenems, Databases, Factual, Drug Resistance, Multiple, Bacterial, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
